Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

Perseus Proteomics to issue warrants to Macquarie, aims to raise ¥470.5 million

Fri, Nov 20, 2026 17:00 JST Perseus Proteomics Inc. (4882.T) Pharmaceutical 中文

Perseus Proteomics Inc. (4882) said on Nov. 20 it will issue 46,000 moving-strike warrants, its 31st series, to Macquarie Bank Limited via third-party allotment, covering 4.6 million potential shares and raising ¥470.5 million based on the initial exercise price of ¥102.

Total proceeds¥470.5 million
Potential shares4.6 million shares
Initial / floor exercise price¥102 / ¥56
Exercise periodDec. 9, 2026-Dec. 8, 2028

The warrants are priced at ¥29 each, or ¥1,334,000 in total, and each converts into 100 shares. Exercising all of them at the initial price would bring in ¥469.2 million, for estimated net proceeds of ¥459.5 million.

From the second exercise onward, the exercise price resets to 92% of the previous trading day's close on the Tokyo Stock Exchange, with no upper limit and a floor of ¥56. The share count remains 4.6 million even at the floor. For exercises classified as exceeding exchange limits, the price cannot fall below the Nov. 20, 2026 close. Proceeds will change if the price is revised or warrants go unexercised.

Founded in February 2001, the antibody drug developer posted an operating loss of ¥744 million and operating cash outflow of ¥653 million for the year ended March 2026. It held ¥1.42 billion in cash and deposits at end-September 2026 and booked an operating loss of ¥412 million for the first half of the fiscal year ending March 2027. The ¥705 million raised through its 29th warrants, issued Jan. 5, 2026, is expected to be fully spent on R&D and operations by end-June 2027.

The company said its antibody-drug conjugate PPMX-T004, developed with UBE Corp., completed preliminary toxicity studies at end-September 2026, and that GLP toxicity studies will require GMP investigational drug manufacturing preparation. It does not currently expect licensing revenue from PPMX-T002 and PPMX-T003.

Next steps: The allotment date is Dec. 8, 2026, and the exercise period runs Dec. 9, 2026-Dec. 8, 2028. The purchase agreement will be signed after the securities registration takes effect.


Original filings
Related